These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 33501437)

  • 1. Host-directed therapies against early-lineage SARS-CoV-2 retain efficacy against B.1.1.7 variant.
    Reuschl AK; Thorne LG; Zuliani-Alvarez L; Bouhaddou M; Obernier K; Hiatt J; Soucheray M; Turner J; Fabius JM; Nguyen GT; Swaney DL; Rosales R; White KM; Avilés P; Kirby IT; Melnyk JE; Shi Y; Zhang Z; Shokat KM; García-Sastre A; Jolly C; Towers GJ; Krogan NJ
    bioRxiv; 2021 Feb; ():. PubMed ID: 33501437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plitidepsin: Mechanisms and Clinical Profile of a Promising Antiviral Agent against COVID-19.
    Papapanou M; Papoutsi E; Giannakas T; Katsaounou P
    J Pers Med; 2021 Jul; 11(7):. PubMed ID: 34357135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A.
    White KM; Rosales R; Yildiz S; Kehrer T; Miorin L; Moreno E; Jangra S; Uccellini MB; Rathnasinghe R; Coughlan L; Martinez-Romero C; Batra J; Rojc A; Bouhaddou M; Fabius JM; Obernier K; Dejosez M; Guillén MJ; Losada A; Avilés P; Schotsaert M; Zwaka T; Vignuzzi M; Shokat KM; Krogan NJ; García-Sastre A
    Science; 2021 Feb; 371(6532):926-931. PubMed ID: 33495306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TMPRSS2 and RNA-Dependent RNA Polymerase Are Effective Targets of Therapeutic Intervention for Treatment of COVID-19 Caused by SARS-CoV-2 Variants (B.1.1.7 and B.1.351).
    Lee J; Lee J; Kim HJ; Ko M; Jee Y; Kim S
    Microbiol Spectr; 2021 Sep; 9(1):e0047221. PubMed ID: 34378968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
    Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F
    Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unraveling the antiviral activity of plitidepsin against SARS-CoV-2 by subcellular and morphological analysis.
    Sachse M; Tenorio R; Fernández de Castro I; Muñoz-Basagoiti J; Perez-Zsolt D; Raïch-Regué D; Rodon J; Losada A; Avilés P; Cuevas C; Paredes R; Segalés J; Clotet B; Vergara-Alert J; Izquierdo-Useros N; Risco C
    Antiviral Res; 2022 Apr; 200():105270. PubMed ID: 35231500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
    Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
    J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathogenesis-directed therapy of 2019 novel coronavirus disease.
    Stratton CW; Tang YW; Lu H
    J Med Virol; 2021 Mar; 93(3):1320-1342. PubMed ID: 33073355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Trimeric Artesunate Analog TF27, a Broadly Acting Anti-Infective Model Drug, Exerts Pronounced Anti-SARS-CoV-2 Activity Spanning Variants and Host Cell Types.
    Hahn F; Wangen C; Häge S; Herrmann L; Herrmann A; Tsogoeva SB; Marschall M
    Pharmaceutics; 2022 Dec; 15(1):. PubMed ID: 36678744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Remdesivir and GS-441524 Retain Antiviral Activity against Delta, Omicron, and Other Emergent SARS-CoV-2 Variants.
    Pitts J; Li J; Perry JK; Du Pont V; Riola N; Rodriguez L; Lu X; Kurhade C; Xie X; Camus G; Manhas S; Martin R; Shi PY; Cihlar T; Porter DP; Mo H; Maiorova E; Bilello JP
    Antimicrob Agents Chemother; 2022 Jun; 66(6):e0022222. PubMed ID: 35532238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of late-onset antiviral treatment in immunocompromised hosts with persistent SARS-CoV-2 infection.
    Lieber CM; Kang H-J; Sobolik EB; Sticher ZM; Ngo VL; Gewirtz AT; Kolykhalov AA; Natchus MG; Greninger AL; Suthar MS; Plemper RK
    J Virol; 2024 Sep; 98(9):e0090524. PubMed ID: 39207133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current Strategies of Antiviral Drug Discovery for COVID-19.
    Mei M; Tan X
    Front Mol Biosci; 2021; 8():671263. PubMed ID: 34055887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiviral Activity of Type I, II, and III Interferons Counterbalances ACE2 Inducibility and Restricts SARS-CoV-2.
    Busnadiego I; Fernbach S; Pohl MO; Karakus U; Huber M; Trkola A; Stertz S; Hale BG
    mBio; 2020 Sep; 11(5):. PubMed ID: 32913009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epigallocatechin-3-Gallate (EGCG) Inhibits SARS-CoV-2 Infection in Primate Epithelial Cells: (A Short Communication).
    Hurst BL; Dickinson D; Hsu S
    Microbiol Infect Dis; 2021; 5(2):. PubMed ID: 35291211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SARS-CoV-2 Variants, Current Vaccines and Therapeutic Implications for COVID-19.
    Liang HY; Wu Y; Yau V; Yin HX; Lowe S; Bentley R; Ahmed MA; Zhao W; Sun C
    Vaccines (Basel); 2022 Sep; 10(9):. PubMed ID: 36146616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plitidepsin: a Repurposed Drug for the Treatment of COVID-19.
    Martinez MA
    Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33558296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Next-generation treatments: Immunotherapy and advanced therapies for COVID-19.
    Arevalo-Romero JA; Chingaté-López SM; Camacho BA; Alméciga-Díaz CJ; Ramirez-Segura CA
    Heliyon; 2024 Mar; 10(5):e26423. PubMed ID: 38434363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell host response to infection with novel human coronavirus EMC predicts potential antivirals and important differences with SARS coronavirus.
    Josset L; Menachery VD; Gralinski LE; Agnihothram S; Sova P; Carter VS; Yount BL; Graham RL; Baric RS; Katze MG
    mBio; 2013 Apr; 4(3):e00165-13. PubMed ID: 23631916
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 24.